FindTrial
Sign In

pembrolizumab 400 mg

BIOLOGICAL2 trials

Sponsors

Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC

Conditions

Gastric CancerHead and Neck CancerMelanomaNon-Small Cell Lung CancerRenal Cell CarcinomaResectable Non-Small-Cell Lung CancerSmall Cell Lung CancerSolid Tumor

Phase 1

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingNCT04198766
Inhibrx Biosciences, IncSolid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer +5
Start: 2019-12-10End: 2033-07-01Target: 340Updated: 2026-07-29

Phase 3

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Active, not recruitingNCT04624204
Merck Sharp & Dohme LLCSmall Cell Lung Cancer
Start: 2020-12-08End: 2027-10-28Target: 672Updated: 2026-09-10

Related Papers

INBRX-106, a novel Hexavalent OX40 agonist, potentiates T-cell receptor clustering, leading to improved activation and potent anti-tumor responses 3058
The Journal of Immunology2025-11-01
HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck cancer with a PD-L1 combined positive score of ≥20.
Journal of Clinical Oncology2025-05-28
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
Journal for ImmunoTherapy of Cancer2025-05-014 citations
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer.
2024-02-01
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
Regular and Young Investigator Award Abstracts2023-10-311 citations
1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
Regular and Young Investigator Award Abstracts2023-10-31
Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.
2022-04-2911 citations
856 INBRX-106: a novel hexavalent anti-OX40 agonist for the treatment of solid tumors
Regular and Young Investigator Award Abstracts2021-11-019 citations
Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs. Concurrent Chemoradiation Therapy in Patients With Newly Diagnosed Limited-Stage Small-Cell Lung Cancer: KEYLYNK-013.
2021-11-01
KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.
Journal of Clinical Oncology2021-05-204 citations